SlideShare una empresa de Scribd logo
1 de 16
CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]
Discovery ,[object Object],[object Object],[object Object],Nature   205 , 698 - 699 (13 February 1965); doi:10.1038/205698a0  Inhibition of Cell Division in  Escherichia coli  by Electrolysis Products from a Platinum Electrode BARNETT ROSENBERG, LORETTA VAN CAMP & THOMAS KRIGAS Biophysics Department, Michigan State University, East Lansing.
Chemotherapeutic agents for Oncology ,[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],J. Med. Chem. 2004, 47, 761-763. ,[object Object],[object Object],[object Object],[object Object],[object Object],Side Effects Nature, 1969, 222, 385-387.
Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site",  Nucleic Acids Res , 1999,  27 , 1837
Structural Requirement ,[object Object],[object Object],[object Object],Reedijk (2003) Proc. Natl. Acad. Sci. USA, 100.(7), 3611-3616.
Sites for Pt binding J. Chem. Ed. 83, 5, 2006 ,[object Object],[object Object]
Mechanism? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],J. Am. Chem. Soc. 2001, 123, 3171-3172 J. Am. Chem. Soc. 2005, 127, 12768-12769
Why not trans? ,[object Object],[object Object],[object Object],[object Object],1:  Eur J Cancer. 1997 Oct;33(11):1823-8  ,[object Object],[object Object]
Analogues ,[object Object],Carboplatin Oxaliplatin Nedaplatin ,[object Object],[object Object]
Future ,[object Object],[object Object],[object Object],Bis(aceto)(1-adamantylamine)aminedichloroplatinum J. Med. Chem., 2004, 47, 761-763
Cytotoxicity Cisplatin-Resistant Tumor Lines   IC 50  ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma  B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7
Questions
Thank You

Más contenido relacionado

La actualidad más candente

Recent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyRecent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyDr. Kunal Chitnis
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsNilesh Kucha
 
Applications of organometallic compounds
Applications of organometallic compoundsApplications of organometallic compounds
Applications of organometallic compoundsPriyanka Jaiswal
 
Phase Transfer Catalysis and Ionic liquids
Phase Transfer Catalysis and Ionic liquids Phase Transfer Catalysis and Ionic liquids
Phase Transfer Catalysis and Ionic liquids Gopika M G
 
Recent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentRecent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentDr. Siddhartha Dutta
 
Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Fari Ba
 
Anticancer drugs
Anticancer drugs        Anticancer drugs
Anticancer drugs Jegan Nadar
 
EGFR -TkI resistance pathways
EGFR -TkI resistance pathways  EGFR -TkI resistance pathways
EGFR -TkI resistance pathways Maria Jubran
 
Chapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitorsChapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitorsNilesh Kucha
 
Soft and hard drugs
Soft and hard drugsSoft and hard drugs
Soft and hard drugsNaresh Juttu
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)Shikha Popali
 
Anti-cancers and their mechanism of action
Anti-cancers and their mechanism of actionAnti-cancers and their mechanism of action
Anti-cancers and their mechanism of actionJoyce Mwatonoka
 
Paterno buchi reaction
Paterno buchi reactionPaterno buchi reaction
Paterno buchi reactionHarish Chopra
 
Dicyclohexylcarbodiimide [DCC]
Dicyclohexylcarbodiimide [DCC]Dicyclohexylcarbodiimide [DCC]
Dicyclohexylcarbodiimide [DCC]Shikha Popali
 
Lanthanide and actinide chemistry
Lanthanide and actinide chemistryLanthanide and actinide chemistry
Lanthanide and actinide chemistrySusovanBhowmik
 

La actualidad más candente (20)

Recent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyRecent advances in Cancer Chemotherapy
Recent advances in Cancer Chemotherapy
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitors
 
Anticancer Activity of Metal Complexes.pptx
Anticancer Activity of Metal Complexes.pptxAnticancer Activity of Metal Complexes.pptx
Anticancer Activity of Metal Complexes.pptx
 
Applications of organometallic compounds
Applications of organometallic compoundsApplications of organometallic compounds
Applications of organometallic compounds
 
Phase Transfer Catalysis and Ionic liquids
Phase Transfer Catalysis and Ionic liquids Phase Transfer Catalysis and Ionic liquids
Phase Transfer Catalysis and Ionic liquids
 
Alkylating agents
Alkylating agentsAlkylating agents
Alkylating agents
 
Recent advances in the Anticancer treatment
Recent advances in the Anticancer treatmentRecent advances in the Anticancer treatment
Recent advances in the Anticancer treatment
 
Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Ruthenium role in cancer therapy
Ruthenium role in cancer therapy
 
Anti Cancer Drugs
Anti Cancer DrugsAnti Cancer Drugs
Anti Cancer Drugs
 
Anticancer drugs
Anticancer drugs        Anticancer drugs
Anticancer drugs
 
EGFR -TkI resistance pathways
EGFR -TkI resistance pathways  EGFR -TkI resistance pathways
EGFR -TkI resistance pathways
 
Chapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitorsChapter 23 topoisomerase inhibitors
Chapter 23 topoisomerase inhibitors
 
Soft and hard drugs
Soft and hard drugsSoft and hard drugs
Soft and hard drugs
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)
 
Anti-cancers and their mechanism of action
Anti-cancers and their mechanism of actionAnti-cancers and their mechanism of action
Anti-cancers and their mechanism of action
 
Wilkinson's catalyst
Wilkinson's catalystWilkinson's catalyst
Wilkinson's catalyst
 
Hammete Equation
Hammete EquationHammete Equation
Hammete Equation
 
Paterno buchi reaction
Paterno buchi reactionPaterno buchi reaction
Paterno buchi reaction
 
Dicyclohexylcarbodiimide [DCC]
Dicyclohexylcarbodiimide [DCC]Dicyclohexylcarbodiimide [DCC]
Dicyclohexylcarbodiimide [DCC]
 
Lanthanide and actinide chemistry
Lanthanide and actinide chemistryLanthanide and actinide chemistry
Lanthanide and actinide chemistry
 

Similar a Cisplatin

Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsMaryam Yekefallah
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursEuropean School of Oncology
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMohamed Abdulla
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Mohamed Abdulla
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclclihua jiao
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerAlok Gupta
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppttttran
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemialarriva
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...isrodoy isr
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxSujan Shrestha
 

Similar a Cisplatin (20)

CRPC management
CRPC managementCRPC management
CRPC management
 
Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materials
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
 
targeted therapy
targeted therapytargeted therapy
targeted therapy
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insight
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019
 
Dr. Goy MCL
Dr. Goy MCLDr. Goy MCL
Dr. Goy MCL
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclc
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancer
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppt
 
7 capdevila
7 capdevila7 capdevila
7 capdevila
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
 
Prostate cancer
Prostate cancer   Prostate cancer
Prostate cancer
 
PhD
PhDPhD
PhD
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
 
Prostate 101
Prostate 101Prostate 101
Prostate 101
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptx
 

Cisplatin

  • 1. CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
  • 7. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14. Cytotoxicity Cisplatin-Resistant Tumor Lines IC 50 ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7

Notas del editor

  1. While studying electric fields and growth of E. Coli/// Rosenberg 1964 Group VIIIb transition metal compounds inhibit cell division 1-10ppm Growth not affected Components of the experimental medium were electrolyzed and tested for the presence of oxidizing agents by reacting with KI/starch solutions. Positive results were found for NH4Cl. NH4)2PtCl6 was formed to be the active agent.
  2. the trans effect is the labilization of ligands trans to certain other ligands, which can thus be regarded as trans directing ligands.
  3. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  4. Preformed Pt- HSA (human serum albumin) administered clinically to patients there was increased survival time. Individuals with low HSA did not respond well to cisplatin Centerwall at Syracuse found using HSQC NMR N15 NMR-h1
  5. Carboplatin cyclobutane dicarboxylate decreases reactivity. Oxaliplatin for colon cancer…oxalate increases water solubility…othermechanisms unknown
  6. Many insecticides show cross resistance Increased reactivity with glutathione may reduce cytotoxicity
  7. Lead compound in future studies of Pt. compounds with hydrophobic ligands. They speculate that the structure of water molecules around adamantineamine affect reaction with glutathione and thiols.